AnGes

JP EN

Pipeline

Main pipeline products

In the nucleic acid medicine and genomic drug discovery businesses, AnGes is promoting three projects: HGF gene therapy products for Chronic arterial occlusive disease, NF-κB decoy oligonucleotide for Chronic discogenic lumber back pain, and the development of DNA vaccines.

Conditional and time-limited approval system

Project Area Partner Code / Dosage Form Indication Basic research Preclinical study Clinical trial Application for Approval Conditional and time-limited approval Launch – Distribution Post Marketing Surveillance Approval
Phase 1 Phase 2
HGF gene therapy product JP Mitsubishi Tanabe Pharma AMG0001
Injection
Chronic arterial occlusive
disease with lower limb ulcer
Approved On sale On going

Approval Process

Project Area Partner Code / Dosage Form Indication Basic research Preclinical study Clinical trial Application for Approval Approval
Phase 1 Phase 2 Phase 3
HGF gene therapy product JP Mitsubishi Tanabe Pharma AMG0001
Injection
Chronic arterial occlusive
disease with rest pain
On going
USA Mitsubishi Tanabe Pharma AMG0001
Injection
Arteriosclerosis obliterans
with lower limb ulcer
P2b
(on going)
Israel Kamada Chronic arterial occlusive
disease with lower limb ulcer
Preparing
for application
Turkey Er-Kim Chronic arterial occlusive
disease with lower limb ulcer
Preparing
for application
NF-κB Decoy
Oligonucleotide
USA AMG0103
Injection
Chronic discogenic
lumber back pain
Completed
DNA Vaccine Australia AMG0201
Injection
Hypertension Completed
DNA Vaccine JP/ Oversea COVID-19 On going
Tie2 agonists USA COVID-19 / ARDS Completed Preparing
for P2a

※In addition to the above projects, the development pipeline includes drugs for chronic hepatitis B and Ebola hemorrhagic fever antiserum in the exploratory, basic research and pre-clinical stages.

Product for HGF gene therapy

NF-κB Decoy Oligo DNA

Vaccine

Contact us